SS Innovations International Inc. filings document a Nasdaq-listed surgical robotics issuer and its formal disclosures around the SSi Mantra platform. Recent Current Reports on Form 8-K record product and regulatory updates, telesurgery announcements, conference-related disclosures, financial-results releases and Regulation FD communications.
The filing record also covers capital structure events, including an unregistered private placement of common stock, and identifies the company’s common stock as registered on Nasdaq under SSII. Annual-report and current-report disclosures provide formal context for operating results, product development, clinical and regulatory timelines, forward-looking statements, and the company’s subsidiary-based reporting perimeter.
SS Innovations International, Inc. director and 10% owner Frederic H. Moll bought 501,253 shares of common stock in an open-market purchase at $3.99 per share. After this transaction, he directly owned 10,775,485 common shares.
SS Innovations International director Timothy P. Adams increased his indirect stake by buying 300,000 common shares in an open-market transaction at $3.99 per share. The shares are held through the Adams Marriage Trust, which now owns 5,331,902 SSII shares for his benefit.
SS Innovations International, Inc. Chairman and CEO Sudhir Srivastava, through Sushruta Pvt. Ltd., made an open-market purchase of the company’s common stock. On March 6, 2026, Sushruta Pvt. Ltd. bought 498,753 shares at $4.01 per share, bringing its indirect holding to 109,851,767 shares.
SS Innovations International reported rapid growth for 2025, with revenue rising to $42.5M from $20.6M, driven mainly by higher SSi Mantra system, instrument, and warranty sales. Fourth quarter 2025 revenue reached $14.5M, up sharply from $8.1M, as installations and surgeries increased.
The company reduced its annual net loss to $12.1M from $19.2M, though operating cash flow was negative at $18.5M. Total assets grew to $74.2M and stockholders’ equity to $38.2M, supported by significant financing, including a post‑quarter private placement raising about $18.6M in gross proceeds.
Management highlighted strong adoption of the SSi Mantra in India, expansion into new geographies, and ongoing work toward U.S. FDA 510(k) review targeted for mid‑2026 and European Union CE marking. They anticipate continued strong growth in 2026 as more systems are deployed and robotic procedures scale.
SS Innovations International, Inc. files its annual report describing rapid expansion in surgical robotics focused on making robotic surgery more affordable, especially in India and other underserved markets. The company’s SSi Mantra system has received Indian CDSCO approval, ISO 13485 certification, and additional clearances in multiple countries.
As of December 31, 2025, SSi Mantra had 168 installed systems across 10 countries and was used in 7,885 procedures, most in general surgery and urology, with more than 120 telesurgeries completed over distances up to thousands of miles. On March 6, 2026, the company completed a private placement of 5,774,839 common shares for gross proceeds of $18,621,498 to fund working capital, global growth initiatives, and preparation for U.S. and EU market entry.
SS Innovations International, Inc. completed a private placement of common stock on March 6, 2026, raising approximately $18.6 million in gross proceeds from the sale of 5,774,839 shares.
The company plans to use the net proceeds for working capital and general corporate purposes, including growth initiatives in India and other existing global markets and preparation for entry into the United States and European Union markets. A $2.5 million non-affiliate investment will trigger a $175,000 cash commission and five-year warrants for 41,667 shares at $3.45 per share to a FINRA member firm. The company expects FDA review of its 510(k) for the SSi Mantra system to be completed by mid-2026 and is pursuing European Union CE marking, which it believes it can obtain in 2026.
SS Innovations International, Inc. executive Barry F. Cohen, COO – Americas, reported an insider transaction involving company common stock. He tendered 32,000 shares of common stock at $6.63 per share to a non-affiliated third-party lender in satisfaction of principal and interest on a $200,000 promissory note. Following this stock-for-debt repayment, he continues to hold 7,806,088 common shares directly.
SS Innovations International, Inc. director and Asia Pacific CEO Vishwajyoti Pascual Srivastava reported a bona fide gift transfer of 2,000,000 shares of common stock. The shares were transferred at a price of $0.00 per share and are held indirectly through Matilda Pvt. Ltd., an entity in which he has a controlling interest. Following the transaction, 2,000,000 shares are reported as indirectly owned through Matilda Pvt. Ltd.
SS Innovations International, Inc. Chairman and CEO Sudhir Srivastava reported a bona fide gift of 2,000,000 shares of common stock. The transfer was made at a reported price of $0.00 per share and is classified as an indirect transaction through Sushruta Pvt. Ltd., which holds the shares of record. Following this gift transfer, indirect holdings reported for this entity total 109,353,014 shares of common stock.
SS Innovations International, Inc. is offering 11,286,681 shares of common stock, with underwriters holding a 45‑day option to buy up to 1,693,002 additional shares. At an assumed price of $4.43, the company expects net proceeds of about $45.8 million (or $52.8 million with the option fully exercised), to fund working capital, manufacturing expansion, clinical trials and global marketing.
SS Innovations is a commercial-stage surgical robotics company selling its SSi Mantra system, with 168 systems installed across 10 countries and 7,885 procedures performed as of December 31, 2025. The business remains loss-making, with 2024 revenue of $20.65 million and a net loss of $19.15 million, and is seeking FDA 510(k) clearance and EU CE certification. Post‑offering, 205,643,381 shares will be outstanding, and the founder and CEO will still control over 55% of voting power, while risks include ongoing losses, financing needs, heavy regulation, data privacy obligations and possible U.S. tariffs.